Biotech Values

[DewDiligence]

New Tysabri survey:

[This supersedes survey #47 from early 2006, which asked whether Tysabri or Copaxone would have larger cumulative sales from 2007-2009. That survey is being retired because it now looks hopeless for Tysabri to catch up to Copaxone during the specified time period.]

Q: Worldwide sales of Tysabri in 2009 will be:

a) Zero
b) More than zero and <$250M
c) $250-499M
d) $500-999M
e) $1B or more

To vote, go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #89.